Inappropriate deposition of fat leads to different forms of diseases, causing morbidity and mortality. The person looks thin despite taking adequate lipid that leads to deposition disorder called lipodystrophy syndrome (LDS). This condition abnormally distributes the fat, where it is not supposed to be deposited. Hence, the patient looks thin and the fats are not in the subcutaneous layer of the skin. It is an autoimmune disease and caused by repeated injection of fat to a particular site. It is classified into two types: generalized and localized lipodystrophy syndrome. Treatment for this syndrome is meterleptin hormone replacement therapy and circulating the site of injection. The prognosis will vary based on the severity of the syndrome.
Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest 2019;42(1):61–73. DOI: 10.1007/s40618-018-0887-z.
“UCLA/VA Researchers discover fat gene.” Archived from the original on 2018-10-06. Retrieved 2017-06-15.
“Lipodystrophy Disorders.” NORD (National Organization for Rare Disorders), https://rarediseases.org/physician-guide/lipodystrophy-disorders/. Accessed 6 Apr. 2020.
Kalyanasundaram AP, Jacob SM, Hemalatha R, Sivakumar MR. Prevalence of Lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural south india. J Int Assoc Physicians AIDS Care (Chic) 2011;11(5):329–334. DOI: 10.1177/1545109 711401750.
Generalized Lipodystrophy: Practice Essentials, Overview, Lipodystrophy, Lipoatrophy, and Lipoatrophic Diabetes. Nov. 2019. eMedicine, https://emedicine.medscape.com/article/128355-overview.
Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 2011;96:3313–3325. DOI: 10.1210/jc.2011-1159.
Herranz P, de Lucas R, Pérez-España L, Mayor M. Lipodystrophy syndromes. Dermatol Clin 2008;26(4):569–578. DOI: 10.1016/j.det.2008.05.004.
Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in Lipodystrophy: a review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism 2019;96:66–82. DOI: 10.1016/j.metabol.2019.05.001.
Bruder-Nascimento T, Kress TC, Belin de Chantemele EJ. Recent advances in understanding Lipodystrophy: a focus on Lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function. F1000Res 2019;8:F1000 Faculty Rev-1756. DOI: 10.12688/f1000research.20150.1.
PMC E. Europe PMC [Internet]. Europepmc.org. 2020 [cited 9 June 2020]. Available from: https://europepmc.org/article/PMC/6798323.
Guillin-Amarelle C, Sanchez-Iglesias S, Castro-Pais A, Rodriguez-Canete L, Ordonez-Mayan L, Pazos M, et al. Type II familial partial lipodystrophy: understanding the Kobberling syndrome. Endocrine 2016;54(2):411–421. DOI: 10.1007/s12020-016-1002-x.
Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 2016;101(12): 4500–4511. DOI: 10.1210/jc.2016-2466 academic.oup.com.
